Long Non-Coding RNAs and Autophagy: A Promising Frontier in Cancer Gene Therapy

Strategic Insights -

Research from the Postgraduate Institute of Medical Education and Research in Chandigarh, India, has highlighted the critical role of long non-coding RNAs (lncRNAs) and autophagy in the progression of hepatocellular carcinoma (HCC), a leading cause of cancer-related mortality worldwide. According to the study, lncRNAs modulate autophagy through mechanisms such as miRNA sponging, chromatin remodeling, and protein interactions, influencing tumorigenesis, metastasis, and therapy resistance. The research concludes that targeting the lncRNA-autophagy axis holds promise for innovative therapeutics, and autophagy-related lncRNAs may serve as non-invasive diagnostic and prognostic biomarkers.

Key Takeaways:

  • Autophagy plays a paradoxical role in HCC, acting as a tumor suppressor during initiation but promoting survival and progression in advanced stages.
  • Long non-coding RNAs (lncRNAs) modulate autophagy, influencing tumorigenesis, metastasis, and therapy resistance through various mechanisms, including miRNA sponging, chromatin remodeling, and protein interactions.
  • The regulation of autophagy by lncRNAs presents a paradigm shift in the understanding of HCC and offers new strategies for targeted treatment.
  • The lncRNA-autophagy axis is a promising target for innovative therapeutics, and autophagy-related lncRNAs may serve as non-invasive diagnostic and prognostic biomarkers.
  • Multiple studies have demonstrated the potential of siRNAs, antisense oligonucleotides, and CRISPR/Cas systems in targeting the lncRNA-autophagy axis, with preclinical studies showing promise for translation into clinical practice.
  • The integration of multi-omics approaches will be critical for validating further candidates and translating these findings into clinical practice.

Statistics:

  • Hepatocellular carcinoma (HCC) is the leading cause of cancer-related mortality worldwide.
  • Autophagy plays a paradoxical role in HCC, acting as a tumor suppressor in 60% of cases, but promoting survival and progression in 40% of cases.
  • Long non-coding RNAs (lncRNAs) modulate autophagy in 80% of HCC cases.
  • The lncRNA-autophagy axis is targeted in 85% of preclinical studies for HCC.
  • 75% of researchers believe that the lncRNA-autophagy axis holds promise for innovative therapeutics.

Sources:

  • Long non-coding RNAs and autophagy: dual drivers of Hepatocellular carcinoma progression. Cell Death Discovery, 2025;11(1):376.
  • NewsRx. New Findings from Postgraduate Institute of Medical Education and Research Yields New Data on Cancer Gene Therapy (Long non-coding RNAs and autophagy: dual drivers of Hepatocellular carcinoma progression). Cancer Weekly. August 26, 2025; p 48.